Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes

Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes ID - 426443 ED - Barry,Henry, ED - Ebell,Mark H, ED - Shaughnessy,Allen F, ED - Slawson,David C, BT - EE+ POEM Archive UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426443/all/Controversial_evidence_on_value_of_pioglitazone__Actos__for_type_2_diabetes PB - John Wiley & Sons DB - Evidence Central DP - Unbound Medicine ER -